Now showing items 1-2 of 2

    • Oncolysis with DTT-205 and DTT-304 generates immunological memory in cured animals 

      Zhou, Heng; Mondragón, Laura; Xie, Wei; Mauseth, Brynjar; Leduc, Marion; Sauvat, Allan; Gomes-da-Silva, Lígia C.; Forveille, Sabrina; Iribarren, Kristina; Souquere, Sylvie; Bezu, Lucillia; Liu, Peng; Zhao, Liwei; Zitvogel, Laurence; Sveinbjørnsson, Baldur; Eksteen, Jacobus Johannes; Rekdal, Øystein; Kepp, Oliver; Kroemer, Guido (Journal article; Tidsskriftartikkel; Peer reviewed, 2018-10-23)
      Abstract Oncolytic peptides and peptidomimetics are being optimized for the treatment of cancer by selecting agents with high cytotoxic potential to kill a maximum of tumor cells as well as the capacity to trigger anticancer immune responses and hence to achieve long-term effects beyond therapeutic discontinuation. Here, we report on the characterization of two novel oncolytic peptides, DTT-205 ...
    • Tumor lysis with LTX-401 creates anticancer immunity 

      Xie, Wei; Mondragon, Laura; Mauseth, Brynjar; Wang, Yan; Pol, Jonathan; Levesque, Sarah; Zhou, Heng; Yamazaki, Takahiro; Eksteen, Jacobus Johannes; Zitvogel, Laurence; Sveinbjørnsson, Baldur; Rekdal, Øystein; Kepp, Oliver; Kroemer, Guido (Journal article; Tidsskriftartikkel; Peer reviewed, 2019-04-13)
      Local immunotherapies such as the intratumoral injection of oncolytic compounds aim at reinstating and enhancing systemic anticancer immune responses. LTX-315 is a first-in-class, clinically evaluated oncolytic peptide-based local immunotherapy that meets these criteria. Here, we show that LTX-401, yet another oncolytic compound designed for local immunotherapy, depicts a similar safety profile and ...